Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apogee Therapeutics, Inc. (APGE) SEC filings page on Stock Titan aggregates the company’s U.S. Securities and Exchange Commission disclosures, providing insight into its status as a Nasdaq-listed, clinical-stage biotechnology issuer. These documents include current reports on Form 8-K, financial statements, equity offering details and other regulatory information that frame Apogee’s development and financing activities in inflammatory and immunology (I&I) therapeutics.
Apogee’s Forms 8-K illustrate how the company reports material events such as quarterly financial results, interim clinical data for programs like APG777 and APG333, and the terms of underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement. Selected 8-Ks also summarize outcomes of the annual meeting of stockholders, including director elections, auditor ratification and advisory votes on executive compensation frequency.
Through these filings, investors can review Apogee’s reported research and development and general and administrative expenses, net losses, cash and marketable securities balances, and the impact of capital raises on its operating runway. Offering-related filings describe underwriting agreements, option exercises by underwriters, pre-funded warrant terms and associated legal opinions, all of which help clarify the structure of Apogee’s capital formation.
On Stock Titan, users can access Apogee’s SEC filings alongside AI-powered summaries that explain the key points of lengthy documents such as earnings-related 8-Ks and registration statement updates. This includes highlighting where the company discusses clinical trial timelines, interim data disclosures, and other items relevant to its I&I pipeline. The filings page also surfaces exhibits like press releases and data presentations incorporated into 8-Ks, as well as cover page information confirming that Apogee’s common stock trades on The Nasdaq Global Market under the symbol APGE.
For those monitoring regulatory developments, capital structure changes or disclosure around programs such as APG777, APG279 and APG333, the SEC filings page offers an organized view of Apogee’s official communications with regulators and investors.
Apogee Therapeutics, Inc. will hold its 2026 virtual annual meeting on June 9, 2026 at 11:00 a.m. Eastern Time to vote on three proposals. Stockholders of record as of April 15, 2026, when 61,853,254 shares of voting common stock were outstanding, may participate.
Investors will elect three Class III directors to terms ending at the 2029 meeting, ratify Ernst & Young LLP as independent auditor for 2026, and cast a non-binding advisory vote on named executive officer pay. The board recommends voting “FOR” all proposals.
The proxy details Apogee’s classified board, supermajority voting for key charter and bylaw changes, and limits on stockholder special meetings and written consents. It highlights a pay-for-performance program in which 2025 bonuses paid at 130% of target, with CEO base salary at $700,000 and other named executives at $540,000.
Apogee Therapeutics, Inc. reported that two directors, Andrew Gottesdiener, M.D. and Peter Harwin, have notified the Board of their intention to resign effective May 11, 2026. The company states these resignations are not due to any disagreement regarding its operations, policies or practices.
Following their departure, the size of the Board will be reduced from nine directors to seven directors, consolidating governance among a smaller group of board members.
Apogee Therapeutics, Inc. Chief Executive Officer Michael Thomas Henderson exercised stock options to acquire 3,000 shares of common stock at $22.86 per share. Following this exercise, he directly holds 1,135,987 shares of common stock.
The exercised options are part of a grant representing the right to purchase 398,512 shares, which vests in forty-eight equal monthly installments over four years, subject to his continued service. After this transaction, 387,012 options from this grant remain outstanding and are scheduled to expire on December 18, 2033.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported an open-market sale of 2,000 shares of common stock at $90.00 per share on April 16, 2026. Following this transaction, she directly holds 175,371 shares of Apogee common stock.
According to a footnote, this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 2, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
Apogee Therapeutics Chief Executive Officer Michael Thomas Henderson reported open-market sales of company common stock. On April 8, 2026, he sold 17,800 shares at a weighted average price of $82.48, 2,000 shares at $83.26, and 200 shares at $85.00.
These transactions were executed under a Rule 10b5-1 trading plan adopted on August 13, 2025, indicating they were pre-scheduled. Following these sales, Henderson directly holds 1,132,987 shares of Apogee Therapeutics common stock.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 10,291,220 shares of Apogee Therapeutics Inc. common stock, equal to 16.8% of the class as reported. The filing shows sole voting power over 9,762,311 shares and sole dispositive power over 10,291,220 shares. The T. Rowe Price Capital Appreciation Fund is disclosed with an interest of 5,295,932 shares (9.7%). The filing is signed and dated by an authorized officer.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski exercised stock options and sold shares in a planned transaction. He exercised options covering 4,125 shares of common stock at an exercise price of $22.86 per share and received 4,125 shares.
On the same date, he sold a total of 5,500 common shares in open-market trades at weighted average prices of about $84.31, $85.33, and $85.89, leaving him with 208,398 directly held shares. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025. A related option grant represents the right to purchase 175,345 shares vesting monthly through December 18, 2027, subject to continued service.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported routine open-market stock sales under a pre-arranged Rule 10b5-1 trading plan. On April 1, 2026, she sold 900 shares of common stock at a weighted average price of $84.46 and 1,100 shares at a weighted average price of $85.46, across multiple trades within disclosed price ranges. After these sales, she held 177,371 shares of common stock directly.
Apogee Therapeutics’ Chief Financial Officer Jane Henderson reported an open‑market sale of 2,000 shares of common stock at $85.00 per share. The transaction took place on March 25, 2026. After this sale, she directly holds 179,371 shares of Apogee common stock.
According to a footnote, this transaction was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 2, 2025. Such plans allow insiders to sell shares according to a preset schedule, reducing the role of day‑to‑day discretion in timing.